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Abstract 
Background: To report on our experience using a simple optional form to facilitate communication on late effects 
between the patients and the oncologists during outpatient follow-up and to detail on the spectrum of challenges 
reported by sarcoma survivors.
Methods: The form was presented for the patients to complete before their consultation and covered topics related 
to late effects and unmet needs that the patient wished to discuss with the medical personnel. Logistic regres-
sion analysis examined how the distribution of the topics varied with age, gender, diagnosis and type of treatment 
received.
Results: The form was manageable in a busy outpatient clinic. Of the 265 patients that received the form, 236 (89%) 
returned it. Patients in a palliative setting and those with other diagnosis than bone sarcoma (BS) and soft-tissue sar-
coma (STS) were excluded for subsequent analyses. The final study-cohort comprised 160 patients, 54 (34%) with BS 
and 106 (66%) with STS. Among these, 140 (88%) had late-effect topics they wanted to discuss with their oncologist. 
Fatigue was raised by 39% of the patients, pain by 29% and impaired mobility by 23%. BS patients raised fatigue more 
often (P < 0.005) than those with STS. Patients who had undergone multimodal treatment with chemotherapy raised 
fatigue more frequently (P < 0.001) than those who had only undergone surgery, radiotherapy or both.
Conclusions: A simple form on the long-term consequences of sarcoma treatment achieved a high response rate, 
was feasible to use in an outpatient clinic and facilitated communication on these issues. Fatigue was the most fre-
quent topic raised and it was raised significantly more often in patients who had undergone chemotherapy.
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Background
A significant proportion of cancer survivors face a range 
of physical and psychosocial long-term consequences fol-
lowing treatment that negatively impact several aspects 
of their lives, leading to a general reduction in well-being 
[1, 2]. The need to address late effects of cancer treat-
ment is widely acknowledged, as demonstrated by studies 
on conditions such as cancer-related fatigue, sexual dys-
function and infertility, pain, cognitive dysfunction, fear 
of recurrence, and disrupted body image [3–6]. However, 
the evidence shows that health care professionals are 
likely to underestimate or misjudge patient health pref-
erences and support needs, especially among young and 
adolescent cancer survivors [7–9].
Treatment of patients with bone sarcoma (BS) and soft-
tissue sarcoma (STS) often involves extensive surgery [10, 
11] that can lead to physical and functional impairments 
[12, 13]. In addition to surgery, curative treatments often 
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chemotherapy, significantly adding to the risk of ther-
apy-related complications [10, 11]. Medical late effects 
include infertility, gonadal hormone deficiency, second 
malignant neoplasms, cardiomyopathy, pulmonary dys-
function, and renal insufficiency [14–17]. BS survivors, 
who are often adolescents and young adults [18], par-
ticularly struggle with late effects following treatment 
[13, 19, 20]. Health concerns among sarcoma survivors 
may be related both directly and indirectly to treatment. 
The patients’ perspective on the impact of late effects has 
not been thoroughly studied. Specifically, it is unknown 
which challenges patients consider most important for 
receiving support and guidance from health care pro-
viders at consultations during long-term outpatient 
follow-up.
A health intervention pilot project was initiated at 
Oslo University Hospital (OUH) after a previous study 
showed that bone cancer survivors reported consider-
able daily life challenges following cancer treatment 
[21, 22]. A simple form was introduced at our sarcoma 
outpatient clinic to facilitate communication between 
patients and oncologists regarding unmet needs. This 
form included well-known physical and psychosocial 
topics for patients to discuss with their clinicians to 
facilitate the patients’ need for information and guid-
ance. The primary aim was to augment the quality of 
late-effect conversations by providing patients time 
before their consultations to ponder their most impor-
tant complaints and by giving the oncologists insights 
and suggestions for topics to discuss with their patients. 
The present study reports on our experiences with this 
form. The secondary aim was to explore which topics 
BS and STS survivors considered the most important to 
discuss with their clinicians, and to determine whether 
there was a relationship between complaints related to 
diagnosis and the type of treatment received, as well as 
to explore any gender differences.
Patients and methods
The Sarcoma Group at the Norwegian Radium Hospi-
tal, OUH, has a catchment area of approximately 2.8 
million people and receive referrals also from other 
health regions in Norway. During systematic follow-up 
of patients treated at our institution, all demographic 
and disease-specific data are stored in a prospective 
clinical sarcoma database. The oncological sarcoma 
outpatient clinics take care of patients who have been 
treated with surgery and additional radiotherapy and/
or chemotherapy. Systematic follow-up is usually 
undertaken for 10  years in expanding time-intervals 
with yearly consultations occurring after 5 years.
Patients
From the start of November 2015 to the end of April 
2016, a total of 383 patients attended the two sarcoma 
outpatient clinics (Fig. 1). A form (Fig. 2) was presented 
to the patients as an optional service before their con-
sultation and handed back to the clinicians at the start 
of the consultation. The form was not provided to any 
patients with evidence of metastases or local relapse 
or if the outpatient clinic that day was excessively busy 
(118 patients). The key information from the form was 
incorporated into the patient’s medical records. Demo-
graphic and disease-specific data were obtained from 
the prospective clinical sarcoma database to identify 
groups according to diagnosis, treatment (curative, 
long-term medical treatment and palliative) and age. 
This study was approved by the local data protection 
officer, and informed consent was obtained from all 
patients.
The present investigation focused on patients with 
STS and BS who had undergone treatment with a cura-
tive intent and who had not had any recurrence of the 
disease. The study excluded 76 patients with gastroin-
testinal stromal tumor (GIST), fibromatosis and other 
diagnoses, resulting in a final study-cohort of 160 
patients (Fig.  1). These patients were stratified into 
two groups according to the type of treatment they 
had received. The first group included patients who 
had been treated with surgery only, surgery and radio-
therapy, or radiotherapy only (SRT). The second group 
comprised patients who had received multimodal treat-
ment including multi-drug chemotherapy (MMT) in 
addition to surgery and or radiotherapy.
The form
A simple form (Fig.  2) to facilitate communication on 
late effects was constructed based on previous qualita-
tive studies in BS survivors [21, 22]. The form covered 
seven topics related to late effects, one box that patients 
could mark if there was any other topic they wanted to 
raise with the clinician and one box that patients could 
mark if they did not have any specific topic to dis-
cuss (Fig. 2). The patients were encouraged to indicate 
a priority of up to two of these topics before the fol-
low-up conversation with the clinician, and they were 
informed that such reporting was voluntary. The form 
was intended to prompt the doctor to secure time that 
day to respond to the topics prioritized by the patient. 
A process would then be initiated to provide general 
information, available printed materials, or referrals to 
other clinical specialists and resources within our hos-
pital environment.
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Statistical analysis
Regarding the descriptive analyses of the demographic 
and clinic data, the Chi squared test or Fischer’s exact 
test was used where appropriate for categorical data. 
The Student’s t-test was used for continuous data (age). 
Associations between the different topics were analyzed 
using the phi coefficient (Ø). Logistic regression analy-
sis was performed to examine how the distribution of 
the topics varied with gender, diagnosis (BS versus STS) 
and treatments (SRT versus MMT). Gender differences 
were adjusted for age, and the differences in diagnosis 
and treatments were adjusted for age and gender. The 
odds ratio (OR) and the adjusted OR are presented with 
95% confidence intervals (95% CI). A two-tailed P value 
of less than 0.05 was considered statistically significant. 
All analyses were performed with the Statistical Pack-
age for the Social Sciences (SPSS) version 21 (SPSS, 
Inc., Chicago, IL).
Results
Patient demographics, diagnoses and treatments
The patient characteristics are summarized in Table 1. Of 
the 160 patients included in this study (Fig.  1), 74 were 
females, and 86 were males. The median age was 55 years 
(range 19–86). The study included 54 (34%) patients 
with BS and 106 (66%) with STS. The participants were 
divided into two groups: 64 (40%) who had undergone 
SRT and 96 (60%) who had undergone MMT. The median 
time from the end of a patient’s cancer treatment to the 
entering study entry was 6 years (range 1–31 years).
Comparing BS and STS, we observed that the median 
age was lower in the BS patients (P < 0.001). Also, the BS 
patients had undergone more MMT than the patients 
with STS (P < 0.001); the STS patients were more fre-
quently treated with SRT and radiotherapy only. No 
significant differences were found related to gen-
der (P = 0.08) or to the time since diagnosis (P = 0.80) 
(Table  1). The patients who had received MMT were 
younger (P < 0.001) and had a longer time since diagno-
sis (P = 0.02), but there were no differences in gender 
between the groups (P = 0.94) (Table 1).
The form
The form was feasible to use in a busy outpatient clinic. 
It was not too time-consuming for the scheduled (20–
30 min) consultations. The response rate was high, as 236 
(89%) of the 265 patients who received the form returned 
it to the clinician (Fig. 1).
In the patients who had undergone curative-intent 
treatment for BS and STS, 140 (88%) of the 160 patients 
had experienced late effects that they wanted to discuss 
with their clinicians. Only 20 patients (12%) reported 
Fig. 1 Consort diagram of the patients in the study
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Fig. 2 The form handed out to the patients. Translated from the Norwegian version into English
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no specific topic that they wished to discuss. Fatigue 
was raised by 39% of the patients, pain by 29%, and 
mobility challenges by 23%. The least used category 
was intestinal/urinary (4% of the patients) (Fig. 3). The 
patients who marked fatigue topic often wanted to dis-
cuss psychological issues (23% versus 4% who did not 
mark fatigue; Ø = 0.30; P < 0.001) and pain (40% versus 
21% who did not mark fatigue; Ø = 0.22; P = 0.005). No 
other significant associations between the topics were 
found. There were no statistically significant gender 
differences in the use of the form (Table  2). However, 
a trend of males marking “no special topic to discuss” 
was found in both the non-adjusted (OR 2.7; 95% CI 
0.9–8.5; P = 0.05) and adjusted analysis (OR 2.9; 95% CI 
0.9–8.3; P = 0.05).
When the topics selected on the form were compared 
to diagnoses, we found that the patients with BS raised 
fatigue (OR 3.1; 95% CI 1.6–6.2; P < 0.001), sexual prob-
lems (OR 2.8; 95% CI 1.1–7.1; P = 0.04), psychological 
problems (OR 3.1; 95% CI 1.2–8.3; P = 0.02) and meet-
ing a peer (OR 5.1; 95% CI 1.3–21; P = 0.02) signifi-
cantly more often than the patients with STS (Table 3). 
Fatigue (OR 3.0; 95% CI 1.4–6.6; P < 0.005) and meet-
ing a peer (OR 10; 95% CI 2.0–54; P = 0.005) remained 
Table 1 Patients characteristics according to diagnosis and treatment groups
Italic values indicate significance of P-value (P < 0.05)
BS bone sarcoma, STS soft tissue sarcoma, SRT surgery and or radiotherapy group, MMT multimodal treatment group
Entire group, 
N = 160 (%)
BS, n = 54 (%) STS, n = 106 (%) P-value SRT, n = 64 (%) MMT, n = 96 (%) P-value
Median age, years (range) 55 (19–86) 39 (19–80) 59 (19–86) < 0.001 66 (28–86) 46 (19–78) <0.001
Gender 0.09 0.94
 Female 74 (46) 30 (56) 44 (41) 30 (47) 44 (46)
 Male 86 (54) 24 (44) 62 (59) 34 (53) 52 (54)
Median time since diagno-
sis, years (range)
6 (0–31) 5 (1–22) 6 (1–31) 0.11 4 (1–19) 6 (1–31) 0.07
Time since diagnosis, years 0.80 0.02
 <5 68 (43) 22 (41) 46 (43) 34 (53) 34 (35)
 ≥5 92 (57) 32 (59) 60 (57) 30 (47) 62 (65)
Treatment group < 0.001
 SRT 64 (40) 9 (17) 55 (52)
 MMT 96 (60) 45 (83) 51 (48)
Fig. 3 Distribution between the topics raised
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Table 2 Topic raised according to gender
OR odds ratio, CI confidence interval, ref reference
a Adjusted for age
Topic Gender N (%) Crude OR (95% CI) P-value Adjusted  ORa (95% CI) P-value
Pain Female 24/74 (32) 1.0 (ref ) 1.0 (ref )
Male 22/86 (26) 0.7 (0.4–1.4) 0.35 0.7 (0.4–1.5) 0.37
Fatigue Female 32/74 (43) 1.0 1.0
Male 31/86 (36) 0.7 (0.4–1.4) 0.42 0.8 (0.4–1.5) 0.41
Bowel/urination Female 4/74 (5) 1.0 1.0
Male 3/86 (4) 0.6 (0.1–2.9) 0.56 0.6 (0.1–3.0) 0.57
Sexual Female 9/74 (12) 1.0 1.0
Male 11/86 (13) 1.1 (0.4–2.7) 0.90 1.1 (0.4–2.9) 0.83
Mobility Female 15/74 (20) 1.0 1.0
Male 21/86 (24) 1.3 (0.6–2.7) 0.53 1.2 (0.6–2.8) 0.48
Psychological Female 8/74 (11) 1.0 1.0
Male 11/86 (13) 1.2 (0.5–3.2) 0.70 1.3 (0.5–3.4) 0.63
Other Female 15/74 (20) 1.0 1.0
Male 8/86 (9) 0.4 (0.2–1.0) 0.05 0.4 (0.2–1.0) 0.05
Peer Female 4/74 (5) 1.0 1.0
Male 6/86 (7) 1.3 (0.4–4.8) 0.68 1.3 (0.3–4.8) 0.79
No topic Female 5/74 (7) 1.0 1.0 0.05
Male 14/86 (17) 2.7 (0.9–8.5) 0.05 2.9 (0.9–8.3)
Table 3 Topic raised according to type of sarcoma
N are presented as number of patients that raised the topic within the diagnosis group with % in the brackets
Italic values indicate significance of P-value (P < 0.05)
STS soft-tissue sarcoma, BS bone sarcoma, OR odds ratio, CI confidence interval, ref reference
a Adjusted for age and gender
Topic Diagnosis N (%) Crude OR (95% CI) P-value Adjusted  ORa (95% CI) P-value
Pain STS 27/106 (26) 1.0 (ref ) 1.0 (ref )
BS 19/54 (35) 1.6 (0.8–3.2) 0.20 1.5 (0.7–3.3) 0.36
Fatigue STS 32/106 (30) 1.0 1.0
BS 31/54 (57) 3.1 (1.6–6.2) 0.001 3.1 (1.4–6.7) 0.004
Bowel/urination STS 5/106 (5) 1.0 1.0
BS 2/54 (4) 0.8 (0.1–4.1) 0.77 0.6 (.01–4.1) 0.59
Sexual STS 9/106 (8) 1.0 1.0
BS 11/54 (20) 2.8 (1.1–7.1) 0.04 2.6 (0.8–7.7) 0.10
Mobility STS 20/106 (19) 1.0 1.0
BS 16/54 (30) 1.8 (0.8–3.9) 0.11 1.9 (0.8–4.5)
Psychological STS 8/106 (8) 1.0 1.0
BS 11/54 (20) 3.1 (1.2–8.3) 0.02 2.9 (0.9–8.5) 0.05
Other STS 14/106 (13) 1.0 1.0
BS 9/54 (17) 1.3 (0.5–3.3) 0.56 1.4 (0.5–4.1) 0.50
Peer STS 3/106 (3) 1.0 1.0
BS 7/54 (13) 5.1 (1.3–21) 0.02 10 (2.0–54) 0.005
No topic STS 16/106 (15) 1.0 1.0
BS 4/54 (7) 0.4 (0.1–1.4) 0.17 0.5 (0.1–1.8) 0.27
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statistically significant when adjusted for age and gen-
der (Table 3). The patients in the MMT group raised the 
topic of fatigue (OR 4.3; 95% CI 2.1–8.8; P < 0.001) and 
mobility (OR 2.4; 95% CI 1.0–5.5; P = 0.04) significantly 
more often than the patients in the SRT group, but only 
fatigue (OR 4.3; 95% CI 1.9–9.5; P < 0.001) remained sta-
tistically significant in the adjusted analysis (Table 4).
As mentioned above, fatigue was moderately associ-
ated with psychological issues and pain. Hence, a mul-
tiple logistic regression analysis including these topics 
together with fatigue, age and sex was performed on 
the diagnosis and treatment groups to ascertain the sig-
nificance of fatigue. In these analyses, fatigue remained 
statistically significant in both the diagnosis (BS: OR 
2.7; 95% CI 1.2–6.0; P = 0.02) and treatment groups 
(MMT: OR 4.5; 95% CI 1.9–10.5; P = 0.001).
In the patients with STS, 51 (48%) underwent MMT, 
and 55 (53%) underwent SRT. The patients in the MMT 
group raised the topic of fatigue (HR 4.2; 95% CI 1.7–
10; P = 0.002) significantly more frequently than the 
patients in the SRT group, even after adjustments for 
age and gender (HR 4.3; 95% CI 1.7–11; P = 0.003). 
No other differences were found between the treat-
ment groups (data not shown). In the patients with 
BS, only nine (17%) patients received SRT, while 44 
(83%) received MMT. Here, no statistically significant 
differences in the use of the form were found (data not 
shown).
Discussion
In the present study, we observed that sarcoma survivors 
were eager to discuss their unmet needs and daily chal-
lenges with their clinicians. To our knowledge, this is first 
study to report a subjective ranking of late effects by sar-
coma survivors in the context of discussing these issues 
with clinicians during long-term follow-up.
A high response was obtained from the form used in 
this study. Among the 160 patients included in this study, 
as many as 140 (88%) indicated a desire to discuss late 
effects with their clinician. Attention to this issue should 
be a vital part of the sarcoma patient follow-up. Our sim-
ple form was easy to use in a busy outpatient clinic and 
did not incur any additional costs. The patients were pro-
vided time to reflect on the topics included in the form, 
allowing them to focus on the conversation that fol-
lowed. In our opinion, the form not only gave the doctor 
insight and suggestions for the follow-up conversations, 
it also increased the patient’s intake and comprehension 
of the conversation content. We hypothesize that this 
improved the quality of the consultation. In addition, 
the form could serve as a clinical survey for recognizing 
whether specific themes are repeated by patients that 
Table 4 Topic raised according to type of treatment
N are presented as number of patients that raised the topic within the treatment group with % in the brackets
Italic values indicate significance of P-value (P < 0.05)
OR odds ratio, CI confidence interval, ref reference, SRT surgery/radiotherapy group, MMT multimodal therapy group
a Adjusted for age and gender
Topic Treatment 
group
N (%) Crude OR (95% CI) P-value Adjusted  ORa (95% CI) P-value
Pain SRT 13/64 (20) 1.0 (ref ) 1.0 (ref )
MMT 33/96 (34) 2.1 (0.9–4.3) 0.06 2.1 (0.9–4.8) 0.07
Fatigue SRT 13/64 (20) 1.0 1.0
MMT 50/96 (52) 4.3 (2.1–8.8) < 0.001 4.3 (1.9–9.5) < 0.001
Bowel/urination SRT 1/64 (2) 1.0 1.0
MMT 6/96 (6) 4.2 (0.5–36) 0.19 5.4 (0.5–54) 0.15
Sexual SRT 6/64 (9) 1.0 1.0
MMT 14/96 (15) 1.7 (0.6–4.5) 0.33 1.3 (0.4–3.9) 0.68
Mobility SRT 9/64 (14) 1.0 1.0
MMT 27/96 (28) 2.4 (1.0–5.5) 0.04 2.4 (0.9–5.8) 0.06
Psychological SRT 6/64 (9) 1.0 1.0
MMT 13/96 (14) 1.5 (0.5–4.2) 0.42 1.0 (0.3–3.2) 0.96
Other SRT 11/64 (17) 1.0 1.0 0.54
MMT 12/96 (12) 0.7 (0.3–1.7) 0.41 05 (0.3–2.0)
Peer SRT 3/64 (5) 1.0 1.0
MMT 7/96 (7) 1.6 (0.4–6.4) 0.51 2.0 (0.4–9.8) 0.36
No topic SRT 11/64 (17) 1.0 1.0
MMT 9/96 (8) 0.5 (0.2–1.3) 0.15 0.4 (0.1–1.3) 0.14
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require special attention and action. As this was a pilot 
study with relatively few patients, this form should pref-
erably be validated in a larger patient cohort. A validated, 
multidimensional, cancer-specific measure of unmet 
needs, such as the SCNS-SF34 [23], could have been 
used in this study. However, it is possible that this may 
not have encompassed needs which are unique to sar-
coma patients. An obvious lack is the topic of mobility, 
since sarcoma survivors experience high rates of physical 
impairment  [12, 13]. To score subjective quality of life in 
patients who have undergone surgery for lower extrem-
ity malignant bone tumor, the Bt-Dux is often used [24]. 
This is, however, not necessarily applicable for patients 
who have undergone heavy chemotherapy. Also, both 
these instruments would probably have been too time-
consuming to use in a busy outpatient clinic. Our results 
demonstrate that a simple communication form regard-
ing late effects, such as the one used in this study, can 
draw attention to late effects for both the patient and the 
clinician and should be considered a routine part of fol-
low-up consultations.
The most prevalent topic raised in the current study 
was fatigue (39%). Fatigue is known to have a multifac-
tored etiology and pathogenesis [3], and it is one of the 
most commonly reported late effects following cancer 
treatment [25]. In sarcoma patients, one study found that 
fatigue was an important problem for more than one-
fourth of the patients who had been treated for a malig-
nant or benign bone or soft tissue tumor [26]. Fatigue is 
probably underreported by patients and underdiagnosed 
by clinicians [27]. The lack of a universally accepted defi-
nition for cancer-related fatigue likely contributes to this 
problem. The National Comprehensive Cancer Network 
has defined fatigue as “a distressing, persistent, subjec-
tive sense of physical, emotional, and/or cognitive tired-
ness or exhaustion related to cancer or cancer treatment, 
that is not proportional to recent activity and interferes 
with usual functioning” [28]. A similar description was 
used in our form. Although fatigue was not the main 
issue studied in this investigation and the questionnaire 
had not been validated for measuring fatigue, patient 
undergoing MMT (including chemotherapy), raised the 
topic of “fatigue-like complaints” significantly more often 
than patients who received only SRT. Patients wanting 
to discuss fatigue does not directly translate to a conclu-
sion that the patients actually had fatigue. However, our 
results imply that fatigue may be more prevalent in sar-
coma patients who have received chemotherapy as part 
of their treatment. This is further reinforced by our find-
ing that BS patients raised the fatigue topic significantly 
more often than patients with STS. BS patients usu-
ally undergo more and longer chemotherapy than STS 
patients [10, 11], as was seen also in our cohort. When 
analyzing fatigue in the STS cohort and comparing the 
SRT and MMT groups, we found that the patient in the 
MMT group also raised the topic of fatigue significantly 
more often than the patients who only received SRT. 
These findings are at odds with the study by Servaes et al. 
[26] who found no differences in patients who received 
adjuvant therapy (including chemotherapy and radio-
therapy). However, in that study, only 25 of 170 patients 
received adjuvant therapy and only 19 received chemo-
therapy, likely too small of a cohort from which to draw 
conclusions. Some research has shown that fatigue may 
be connected to a premorbid personality with neuroti-
cism, poor communication and social functioning [29]. 
Higher emotional instability and self-reported stress in 
the premorbid period has been associated with a higher 
risk for chronic fatigue-like illness [30]. Across stud-
ies, the strongest and most consistent predictor of post-
treatment fatigue is pre-treatment fatigue [3], but there is 
evidence that chemotherapy plays a role in fatigue devel-
opment, as reported in a recent meta-analysis of breast 
cancer survivors [31]. Our findings support this notion 
and indicate that premorbid conditions should not be 
used an excuse to avoid justified guidance and support.
Fatigue and depression are strongly correlated in can-
cer [3], but it is difficult to determine whether fatigue 
is a symptom or a trigger of depression. Patients may 
attribute their depression symptoms to a less stigmatized 
state, e.g., as a somatic explanation that is translated into 
fatigue. Alternatively, fatigue may precipitate depressive 
moods by interfering with social, work-related and lei-
sure activities. In the present study, the desire to discuss 
fatigue was moderately associated with raising the topic 
of psychological issues. However, when data were con-
trolled for psychological issues, fatigue remained statisti-
cally significant. As for other previously reported studies 
[3], we cannot discern the causality between fatigue 
and depression. Nevertheless, a simple form such as the 
one used in our study may draw attention to both top-
ics, revealing the nature of the complaints and guiding 
proper interventions.
Although fatigue awareness and the number of stud-
ies on the issue have increased in recent years, a focus on 
fatigue has not yet become routine during clinical follow-
up [32]. According to the present findings, this practice 
should be adopted, especially in sarcoma patients who 
have received chemotherapy.
Pain (29%) and mobility (23%) were important topics to 
discuss for the patients. The patients in the present study 
attended orthopedic and abdominal sarcoma surgeons’ 
outpatient clinics in addition to our outpatient clinic. 
Hence, we cannot exclude that the patients focused 
on other topics at these oncological outpatient clinics 
and raised mobility topics more frequently with their 
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surgeons. Interestingly, there were no statistically signifi-
cant differences in the use of the form between genders. 
Whether the late effects of sarcoma treatment are uni-
versal to both genders cannot be answered by our study. 
There was, however, a trend toward males using “no 
topic to discuss” more frequently than females. In a larger 
patient cohort, this trend may have reached significance.
There are some limitations to the present study. As 
previously mentioned, the form used to score the late 
effects among patients and to facilitate communication 
between the clinician and the patient had not been vali-
dated. Since this was a pilot study integrated into a busy 
oncology practice, we chose to present the patients with 
a simple form. The majority of our patients responded to 
the form, and its use was manageable for the clinicians 
given the time available. To properly report on the issue 
of fatigue from a methodological perspective, a validated 
questionnaire [33] to score the symptoms and severity of 
fatigue would have been preferred. Due to the sample size 
and limited power, analyses of the interactions among 
the topics were not performed. The statistical power of 
the study was limited by the relatively small number of 
patients within the groups, implying a risk of type II sta-
tistical errors. Despite these limitations, we believe that 
our data accurately represent the clinical experiences of a 
busy oncological outpatient clinic.
Conclusion
A simple form on the long-term consequences of sar-
coma treatment achieved a high response rate, was 
feasible to use in an outpatient clinic and facilitated 
communication on these issues. Fatigue was the most 
prevalent topic raised by sarcoma patients, followed by 
pain and mobility. Fatigue was raised significantly more 
often among those who had undergone treatment with 
chemotherapy.
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